Literature DB >> 7524038

Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms.

O Zelphati1, J L Imbach, N Signoret, G Zon, B Rayner, L Leserman.   

Abstract

Phosphodiester and phosphorothioate oligonucleotides in alpha and beta configurations directed against the initiation codon region of the HIV-1 rev gene were evaluated for their ability to inhibit HIV-1 replication in acutely and chronically infected human CEM cells. Encapsulation in antibody-targeted liposomes (immunoliposomes) permitted intracellular delivery and distinction between oligonucleotide-mediated inhibition of viral entry and intracellular effects on viral RNA. Our results are consistent with four mechanisms of antiviral activity for these antisense oligonucleotides: (i) interference with virus-mediated cell fusion by free but not liposome-encapsulated phosphorothioate oligonucleotides of any sequence; (ii) interference with reverse transcription in a sequence non-specific manner by phosphorothioate oligonucleotides in alpha and beta configurations; (iii) interference with viral reverse transcription in a sequence-specific and RNase-H-independent manner by alpha and beta phosphodiester oligonucleotides; (iv) interference with viral mRNA in a sequence-specific and RNase-H-dependent manner by beta-phosphorothioate oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524038      PMCID: PMC331952          DOI: 10.1093/nar/22.20.4307

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  49 in total

1.  alpha-DNA. VI: Comparative study of alpha- and beta-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibition.

Authors:  C Gagnor; J R Bertrand; S Thenet; M Lemaître; F Morvan; B Rayner; C Malvy; B Lebleu; J L Imbach; C Paoletti
Journal:  Nucleic Acids Res       Date:  1987-12-23       Impact factor: 16.971

2.  Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide.

Authors:  C Majumdar; C A Stein; J S Cohen; S Broder; S H Wilson
Journal:  Biochemistry       Date:  1989-02-07       Impact factor: 3.162

3.  Colorimetric determination of phospholipids with ammonium ferrothiocyanate.

Authors:  J C Stewart
Journal:  Anal Biochem       Date:  1980-05-01       Impact factor: 3.365

4.  Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.

Authors:  M Matsukura; G Zon; K Shinozuka; M Robert-Guroff; T Shimada; C A Stein; H Mitsuya; F Wong-Staal; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

5.  Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.

Authors:  P C Zamecnik; J Goodchild; Y Taguchi; P S Sarin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

6.  Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120.

Authors:  C A Stein; A M Cleary; L Yakubov; S Lederman
Journal:  Antisense Res Dev       Date:  1993

7.  Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes.

Authors:  S Z Salahuddin; P D Markham; F Wong-Staal; G Franchini; V S Kalyanaraman; R C Gallo
Journal:  Virology       Date:  1983-08       Impact factor: 3.616

8.  Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.

Authors:  M Matsukura; K Shinozuka; G Zon; H Mitsuya; M Reitz; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

9.  Oligodeoxynucleotide stability in subcellular extracts and culture media.

Authors:  E Wickstrom
Journal:  J Biochem Biophys Methods       Date:  1986-09

10.  Antiviral activity of conjugates between poly(L-lysine) and synthetic oligodeoxyribonucleotides.

Authors:  J P Leonetti; B Rayner; M Lemaitre; C Gagnor; P G Milhaud; J L Imbach; B Lebleu
Journal:  Gene       Date:  1988-12-10       Impact factor: 3.688

View more
  12 in total

1.  Antisense delivery using protamine-oligonucleotide particles.

Authors:  M Junghans; J Kreuter; A Zimmer
Journal:  Nucleic Acids Res       Date:  2000-05-15       Impact factor: 16.971

2.  The spherulites(TM): a promising carrier for oligonucleotide delivery.

Authors:  N Mignet; A Brun; C Degert; B Delord; D Roux; C Hélène; R Laversanne; J C François
Journal:  Nucleic Acids Res       Date:  2000-08-15       Impact factor: 16.971

3.  Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide.

Authors:  V Prasad; S Hashim; A Mukhopadhyay; S K Basu; R P Roy
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication.

Authors:  C Lavigne; J Yelle; G Sauvé; A G Thierry
Journal:  AAPS PharmSci       Date:  2001

5.  In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides.

Authors:  O Vidalin; M E Major; B Rayner; J L Imbach; C Trépo; G Inchauspé
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  Cationic liposome-encapsulated antisense oligonucleotide mediates efficient killing of intracellular Leishmania.

Authors:  R Chakraborty; D Dasgupta; S Adhya; M K Basu
Journal:  Biochem J       Date:  1999-06-01       Impact factor: 3.857

7.  Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides.

Authors:  Charles M Roth
Journal:  Biophys J       Date:  2005-07-29       Impact factor: 4.033

8.  Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes.

Authors:  R Z Yu; R S Geary; J M Leeds; T Watanabe; J R Fitchett; J E Matson; R Mehta; G R Hardee; M V Templin; K Huang; M S Newman; Y Quinn; P Uster; G Zhu; P K Working; M Horner; J Nelson; A A Levin
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

9.  Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles.

Authors:  M Berton; P Turelli; D Trono; C A Stein; E Allémann; R Gurny
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

10.  New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.

Authors:  O A Patutina; N L Mironova; V V Vlassov; M A Zenkova
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.